Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma

Huber, Gerhard; Albinger-Hegyi, Andrea; Soltermann, Alex; Roessle, Matthias; Graf, Nicole; Haerle, Stephan K.; Holzmann, David; Moch, Holger; Hegyi, Ivan

doi:10.1002/cncr.26100

Cited by 61 publications

(76 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p16 is a tumor suppressor encoded by the INK4a/Arf locus. p16 inhibits cyclin D1-cyclin dependent kinase complex that acts through phosphorylation of tumor suppressor Rb [4]. After phosphorylation, Rb protein becomes inactive, which enables the cell cycle to progress and tumor growth.…”

Section: Introductionmentioning

confidence: 99%

“…BMI-1 regulates genes involved in the cell cycle and cell differentiation and can, therefore, act as a potent oncogene [6,7]. BMI-1's effect is mediated partly through repression of the INK4a/ARF, a locus encoding p16 [4]. Upregulation of BMI-1 leads to repression of p16.…”

Section: Introductionmentioning

confidence: 99%

“…BMI-1 expression has been linked with both better and worse survival of cancer patients. In OPSCC and laryngeal squamous cell carcinoma an inverse relation between p16 and BMI-1 expression has been reported to affect tumor stage and patient survival [4,13]. In this study we investigated the expression of p16 and BMI-1 in OPSCC, oral (OSCC), hypopharyngeal (HPSCC), and laryngeal (LSCC) squamous cell carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas

Lundberg

Renkonen

Haglund

et al. 2016

Acta Oto-Laryngologica

View full text Add to dashboard Cite

A A 2016 , ' Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas ' Acta Oto- Laryngologica , vol. 136 ,no. 5 , Conclusions BMI-1 is an upstream repressor of tumor suppressor p16 and their inverse expression patterns have been linked with patient survival in OPSCC. In this material only p16 remained a relevant prognostic marker in OPSCC. Objectives HNSCC tumors carry variable phenotypes and clinical outcomes depending on their anatomical location. In OPSCC, expression of tumor suppressor p16 is used as a surrogate marker of HPV infection and has prognostic value. There are no good prognostic biomarkers for HNSCC tumors of other anatomical locations. Aim To study the expression patterns of p16 and BMI-1 in not only oropharyngeal but also oral, hypopharyngeal, and laryngeal squamous cell carcinomas and to clarify their putative connections with clinical parameters, survival, and each other. Method Hospital records on 130 patients (59 OPSCC, 18 OSCC, 20 HPSCC, and 33 LSCC) diagnosed between 1997-2008 at the Helsinki University Hospital, Finland, were reviewed. BMI-1 and p16 expressions were studied by immunohistochemistry. Results Sixty-eight per cent of OPSCC expressed p16 and expression correlated with lower age, lower T-and higher N-category, and with improved OS and DFS. BMI-1 expression was most prevalent in OPSCC and LSCC, but had no clinical correlations. No correlation between p16 and BMI-1 expression was found.ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas

Lundberg

Renkonen

Haglund

et al. 2016

Acta Oto-Laryngologica

View full text Add to dashboard Cite

show abstract

“…Epithelial-mesenchymal transition (EMT) is the key process driving cancer metastasis and BMI-1 has been demonstrated to induce EMT in endometrial carcinoma cells (28). Furthermore, in vivo studies revealed that BMI-1 expression was upregulated in cancer tissues compared with matched healthy tissues and was associated with distant metastases of gastric cancer (8,29), HCC (15), lung cancer (14,30,31), endometrial carcinomas (16,28,32), and head and neck cancer (11,12,33). Several previous studies have also suggested that BMI-1 contributed to mammary carcinogenesis, axillary lymph node metastases, highly aggressive behavior and late-stage relapse in breast cancer (6,10,(34)(35)(36).…”

Section: Bmi-1 and Cancermentioning

confidence: 99%

BMI-1, a promising therapeutic target for human cancer

Wang

Cui

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. BMI-1 oncogene is a member of the polycomb-group gene family and a transcriptional repressor. Overexpression of BMI-1 has been identified in various human cancer tissues and is known to be involved in cancer cell proliferation, cell invasion, distant metastasis, chemosensitivity and patient survival. Accumulating evidence has revealed that BMI-1 is also involved in the regulation of self-renewal, differentiation and tumor initiation of cancer stem cells (CSCs). However, the molecular mechanisms underlying these biological processes remain unclear. The present review summarized the function of BMI-1 in different human cancer types and CSCs, and discussed the signaling pathways in which BMI-1 is potentially involved. In conclusion, BMI-1 may represent a promising target for the prevention and therapy of various cancer types.

show abstract

“…(146) BMI1 is reported to play a crucial role in self-renewal of stem cells and is associated with a number of human malignancies. (141,144,(147)(148)(149) Recent studies suggest that BMI1 is involved in the initiation of cancer, and targeting BMI1 by gene therapy abolishes chemoresistance in tumor cells. (141,142) The inability of tumor cells to go through apoptosis in response to chemotherapy gives a selective advantage for tumor progression, metastasis, and resistance to therapy.…”

Section: Csc Conceptmentioning

confidence: 99%

Cancer Stem Cell Hypothesis: Implication for Cancer Prevention and Treatment

Meiliana

Dewi²,

Wijaya

2016

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: Cancer is a disease of genomic instability, evasion of immune cells, and adaptation of the tumor cells to the changing environment. Genetic heterogeneity caused by tumors and tumor microenvironmental factors forms the basis of aggressive behavior of some cancer cell populations.CONTENT: Cancers arise in self-renewing cell populations and that the resulting cancers, like their normal organ counterparts, are composed of hierarchically organized cell populations. Self – renewing “cancer stem cells” (CSC) maintain tumor growth and generate the diverse populations constituting the tumor bulk. CSCs in multiple tumor types have been demonstrated to be relatively resistant to radiation and chemotherapy. The clinical relevance of these studies has been supported by neoadjuvant breast cancer trials that demonstrated increases in the proportions of CSCs after therapy. The CSC hypothesis has tremendously important clinical implications.SUMMARY: In summary, a large and accumulating body of evidence supports the CSC hypothesis, which has important implications for cancer prevention and therapy. The ultimate test of this hypothesis will require clinical trials demonstrating that targeting of these pathways reduces cancer incidence and improves outcomes for patients with cancer.KEYWORDS: Somatic mutation, tumor heterogeneity, metastasis, epithelial-mesenchymal transition, CSC niche

show abstract

Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma

Cited by 61 publications

References 49 publications

Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas

Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas

BMI-1, a promising therapeutic target for human cancer

Cancer Stem Cell Hypothesis: Implication for Cancer Prevention and Treatment

Contact Info

Product

Resources

About